# Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial

> **NCT00407797** · PHASE4 · TERMINATED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 136 (actual)

## Conditions studied

- Partial Seizures

## Interventions

- **DRUG:** Pregabalin

## Key facts

- **NCT ID:** NCT00407797
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00407797

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00407797, "Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT00407797. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*